The National Institutes of Health’s Post

In the spotlight!🔎 Today's Eurorad case features a 78-year-old Asian male, with newly diagnosed distal sigmoid and high rectal cancer, presented with chronic anorexia, fatigue, and general malaise. Labs were significant for elevated liver enzymes, decreased hemoglobin and hematocrit, and mild leukocytosis. Initial computed tomography (CT) of the abdomen and pelvis with contrast demonstrated a large ill-defined hepatic lesion measuring up to 23.6 cm, with areas of central hypodensity, septations, and a hyperdense rim that showed mild enhancement beginning in the arterial phase, with gradual enhanced enhancement of internal septations on the portal venous phase with areas of hypoattenuation that persisted on delayed imaging . End of
Translation Because these findings were nonspecific, a percutaneous core-needle biopsy of the liver mass was performed 4 weeks after initial CT. Take a look at the full case and diagnosis 🔗

#snsinstitutions #snsdesignthinkers #designthinking **Exploring Sarcoma: Unraveling the Intricacies of Connective Tissue Cancers** Sarcoma is a rare but diverse group of cancers that originate in the body's connective tissues, including bones, muscles, tendons, and cartilage. Understanding the characteristics, subtypes, and treatment options for sarcomas is crucial for patients and healthcare professionals alike. **Types of Sarcoma:** 1. **Soft Tissue Sarcoma:** Arising in soft tissues like muscles, tendons, and fat. 2. **Bone Sarcoma:** Developing in the bones and often categorized as osteosarcoma or Ewing sarcoma. 3. **Gastrointestinal Stromal Tumor (GIST):** Affecting the digestive tract, particularly the stomach and small intestine. **Causes and Risk Factors:** 1. **Genetic Factors:** Inherited genetic mutations may predispose individuals to certain types of sarcoma. 2. **Radiation Exposure:** Previous radiation treatment may increase the risk of developing sarcoma. 3. **Chemical Exposure:** Contact with certain chemicals has been linked to the development of sarcomas. **Symptoms:** 1. **Lump or Mass:** Often the first noticeable sign, especially in soft tissue sarcomas. 2. **Pain or Tenderness:** Persistent pain at the tumor site or limited range of motion. 3. **Fractures:** Bone sarcomas may cause bone weakness and fractures. **Diagnosis and Staging:** 1. **Biopsy:** Tissue samples are examined to confirm the presence of sarcoma and determine its type. 2. **Imaging:** CT scans, MRIs, and X-rays help assess the size and extent of the cancer. **Treatment Options:** 1. **Surgery:** Removal of the tumor is a common approach, often combined with radiation therapy. 2. **Chemotherapy:** Medications to kill or slow the growth of cancer cells, especially for advanced cases. 3. **Targeted Therapy:** Drugs that target specific molecules involved in cancer growth. **Prognosis:** The prognosis for sarcoma varies widely based on factors such as the type, stage, and location of the cancer. Early detection and comprehensive treatment contribute to better outcomes. **Ongoing Research and Innovation:** Advancements in understanding sarcoma genetics and molecular pathways are paving the way for targeted therapies and personalized treatment approaches. Clinical trials continue to explore new and promising treatments. **Support and Coping:** Facing a sarcoma diagnosis can be challenging, and support from healthcare professionals, support groups, and loved ones is essential. Coping strategies, including mental health support, play a crucial role in the overall well-being of patients. In conclusion, sarcoma presents a unique set of challenges due to its rarity and diverse subtypes. Early detection, multidisciplinary treatment approaches, and ongoing research are key components in improving outcomes for individuals affected by sarcoma.

74 Year old Female presented with Clinical History: Odynophagia, dysphagia and weight loss. Found on OGD to have hypho-pharyngeal tumour. HISTOPATHOLOGY REPORT- HYPOPHARYNGEAL BIOPSIES Diagnosis: Poorly Differentiated Non-Keratinizing Squamous Cell Carcinoma. CE Neck CT revealed Findings of a Large circumferential mural thickening is seen implicating the whole hypopharynx just 1.5cm caudally from the hyoid bone level, measuringI4.3x7.2cm at its maximumn axial dimensions, extending inferiorly to invade the upper esophageal mucosa and laterally to encasing the left carotid artery, posteriorly to be inseparable from the pre-vertebral fascia and anteriorly indenting the posterior aspect of the trachea and shifting it to the right side. The aforementioned mass lesion showing areas of internal breaking down, no calcifications, with large intra-luminal component causing marked luminal narrowing along its whole hypopharynx and upper esophageal portion. Left deep cervical few pathologically enlarged lymph nodes.

Case of the month from Onco Pathology: Giant Cell Tumor of the Bone In this month's edition of our monthly case series, where we discuss the most interesting cases we encountered at Our Center, we're diving into an intriguing pathology case featuring an Giant Cell Tumor of the Bone. Clinical History: 67 years old male, known hypertensive patient on treatment, presenting with right side chest pain of 1 week duration. He also had weight loss and loss of appetite. Previously, he was treated with anti-TB (6 month with completion) for similar symptoms. Case diagnosis: Giant Cell Tumor of the Bone (GCT) Case Discussion: Giant cell tumors are benign, though aggressive, neoplasms, accounting for 5 to 9 percent of all primary bony tumors. Giant cell tumors are usually found in the long bones, most often the distal femur, proximal tibia, and distal radius. GCT rarely arises in ribs (<1% in most series). The origin remains unknown. The giant cells may be derived from fused stromal cells of mononuclear phagocytic lineage. GCT are generally considered benign but malignant cells can arise de novo or via transformation from a benign neoplastic giant cell lesion. Giant cells are ubiquitous in bone lesions. A wide array of lesions may histologically mimic, depending on the quality and size of the biopsy. To conclude, this case demonstrates the fact that giant cell tumors of the chest wall and the multicentricity can be mistaken for other malignant tumors of bone and soft tissues. Don't miss out on the opportunity to explore this fascinating case study and expand your knowledge in the field. Click the link below to access the complete case document. https://lnkd.in/eprMwQnA... 0949045555 | 0949112211| 0949000066 #ONCOPathology #PathologyCases #GCT #GiantCellTumor #MedicalKnowledge @oncopathologydiagnosticcenter

☢️ Destructive NHL ☢️ a 58-year-old female was found to have destructive hypermetabolic manubrium soft tissue mass with lobulated margins protruding anterior beyond the bony margins to the anterior chest wall and extending posteriorly to the anterior mediastinum abutting and compressing the left brachiocephalic vein. Another hypermetabolic right acetabular and pubic bone destructive bone lesion with soft tissue component protruding beyond the bony margins, associated with hypermetabolic right iliac bone lytic deposits with cortical permeative pattern. There were also hypermetabolic prominent sized cervical and mediastinal lymph nodes, a large right obturator nodal mass, and focal areas within the right atrial walls. Biopsy confirmed NHL/DLBC. . . 🗓️ Large B-cell lymphoma is the most common subtype of non-Hodgkin's lymphoma characterized by its rapid growth and aggressive behavior. It originates from B white blood cell responsible for producing antibodies. It typically presents with enlarged lymph nodes, fever, night sweats, and weight loss. Aggressive large B-cell lymphoma can affect various organs, including the lymph nodes, bone, liver, and spleen. Tumor-induced destruction of the cortical bone can occur due to lymphoma spreading from the bone marrow into the bony cortex, or when extramedullary lymphoma infiltrates the nearby cortical bone. . . . . #radiology #radiologist #nuclearmedicine #nucmed #radtech #medicinanuclear #medicalshool #jordan #nucmedtech #futureradiologist #EANM23 #SNMMI23 #radiologie #radiologyresident #radiologyrounds #bone #radiographer #xray #xrays #imaging #surgery #futuredoctor #medschool #mri #cancer #tumor #oncology #lesion #pet #petct #suv #hypermetabolic #fdg

Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: a multicentre, prospective, diagnostic, clinical trial The Lancet https://lnkd.in/gPYQrj7K

AMLo Biosciences would like to share a greater understanding of the risk between #melanoma #lymphoedema gained from a presentation at the Melanoma Focus patient conference earlier this year. Consultant Plastic Surgeon, Mr Alex Ramsden, explained the process and consequence of #lymphoedema that can occur following lymph node removal. In #melanoma patients, metastatic regional lymph nodes are currently treated by surgical excision, which can result in lymphatic obstruction and chronic lymphoedema. This affects around 49–83% of lower limbs when inguinal lymph nodes are removed and 4–21% of upper limbs following axillary lymph node dissection in melanoma patients. Lymphoedema is poorly understood. It is a chronic, progressive condition that involves not only fluid retention but fat deposition in affected limbs. It is important that symptoms are recognised and dealt with as early as possible. Lymphoedema not only has physical effects but can also have serious psychological consequences with an estimated 400,000 patients hiding chronically swollen limbs. Cellulitis can be a further consequence of chronic lymphoedema that can lead to a life-threatening infection. Mr Alex Ramsden explained that this under recognised by many of the medical professions and that access to treatment can be limited. A recording of his full presentation can be found here https://bit.ly/3Cvx9wc. AMLo hope that better risk stratification of early-stage melanomas could help to avoid the need for lymph node removal in some melanoma patients. amlo-biosciences.com #dermatology #dermatopathology #histopathology #oncology #skincancer #lymphedema #lymphoedemaawareness

I am so Happy to have this work of ours recently published in Blood Cell Therapy, The official journal of Asia-Pacific Blood and Marrow Transplantation Association. We addressed a challenging issue in this article for relapsing/ refractory Hodgkin Lymphoma patients who undergo hematopoietic stem cell transplantation, especially those who reside in developing societies. As evident, these patients are prone to recurrent relapse and high degrees of mortality. Recent advances in the transplant medicine have introduced "Brentuximab Vedotin" as the standard maintenance therapy, however, access to this drug is expensive and limited in developing countries, and for those with low socio-economic status. In this article we evaluated a replacement therapy with a more available and affordable agent " Everolimus" over the course of 2 years. results are promising! Medicine should be accessible for everyone. It is of paramount importance to have long term research visionaries for finding more available and affordable agents for life changing procedures such as HSCT. Happy to be part of this path as a physician-scientist. Many thanks to amazing Dr. Mahshid Medizadeh, for mentoring all of us in this great mission. #HSCT #hodgkin #lymphoma #health_for_all #medicine #transplant_medicine #dermatology_in_transplant_medicine

AMLo Biosciences agree with the conclusions of an article recently published in the US Journal of Clinical Oncology. In this paper, the authors debate the arguments for and against sentinel lymph node biopsy (SLNB) in the management of cutaneous #melanoma. They explain that current management protocols usually involve SLNB and wide local excision despite the fact that the disease most commonly presents without nodal metastases e.g. early-stage I/II melanoma. In addition, the article notes that recent research and developments in the field, bring current management strategies into question. “Not every treatment is right for every patient, and #biomarker development in the adjuvant therapy space is perhaps the greatest unmet need in melanoma #oncology.” The authors conclude that melanoma management goals should be “to optimize individual outcomes with regard to recurrence and survival while minimizing toxicity and cost to both the individual and health system”.  https://bit.ly/3LEmbtm Here at AMLo, we agree that there needs to be a better understanding of how SLNB fits into the overall management of melanoma. We firmly believe that our #AMBLor prognostic technology can significantly improve patient experience and save precious clinical resources. See www.amlo-biosciences.com. #dermatology #dermatopathology #histopathology #skincancer #cancerimmunology #cancerresearch

BioProtect Ltd 𝗿𝗲𝗰𝗲𝗶𝘃𝗲𝘀 𝗙𝗗𝗔'𝘀 𝗰𝗹𝗲𝗮𝗿𝗮𝗻𝗰𝗲 𝗳𝗼𝗿 #BioProtect Balloon Implant System✅ BioProtect Ltd. has received FDA Clearance for the BioProtect Balloon Implant System. The biodegradable #balloon is a new-gen spacer designed to provide protection to the rectum during #prostatecancer radiation therapy. #Prostate Cancer is the 2nd most common cancer in men in the US, with 288,300 new cases so far in 2023. While radiation therapy is an effective treatment option, it can cause a number of side effects including increased pain and frequency with urination, rectal pain and bleeding, erectile dysfunction, fatigue and increased risk of infection. Itay Barnea, CEO, said "We believe that our balloon has the potential to revolutionize rectal protection from toxicity during prostate cancer radiation therapy. Not only does it provide better protection to healthy organs, it also supports dose escalation and hypofractionation, which are leading trends in prostate cancer radiation therapy." #medicaldevices #medtech #fdacleared #urology #menshealth #prostatecancer #cancertreatment #oncology #startup #innovation #healthcare #executivesearch #recruitment